Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
Reid W. Merryman(Harvard University), Massimo Magagnoli(Humanitas University), Ryan C. Lynch(Seattle Cancer Care Alliance), Lori Dahncke(Hackensack Meridian Health), Jonathon B. Cohen(Emory University), Aspasia Stamatoulas Bastard(Centre Henri Becquerel), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), Mehdi Hamadani(Medical College of Wisconsin), Geoffrey Shouse(City Of Hope National Medical Center), Tatyana Feldman(Hackensack University Medical Center), Mohamad Mohty(Sorbonne Université), Luca Castagna(Humanitas University), Didier Blaise(Institut Paoli-Calmettes), Robin Joyce(Beth Israel Deaconess Medical Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Alex F. Herrera(City of Hope), Roch Houot(Inserm), Yi‐Bin Chen(Massachusetts General Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Hatcher J. Ballard(University of Pennsylvania), Anurag K. Singh(University Medical Center), Robert Lowsky(Stanford University), Chiara De Philippis(IRCCS Humanitas Research Hospital), Sally Arai(Stanford Medicine), Michael Byrne(Vanderbilt University Medical Center), Asad Bashey, David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joseph P. McGuirk(University of Kansas Medical Center), Chloé Spilleboudt(Institut Jules Bordet), Martina Sollini(Humanitas University), Paolo Corradini(Gruppo di Ricerca Geriatrica), Guillaume Manson(Hôpital Pontchaillou), Jean‐Marc Schiano de Colella(Centre de Recherche en Cancérologie de Marseille), Stephen M. Ansell(Mayo Clinic), Anna Guidetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Matthew J. Frigault(Harvard University), Beatrice Casadei(Istituto di Ematologia di Bologna), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Rémy Duléry(Dana-Farber Cancer Institute), Jason T. Romancik(Emory University), Talha Badar(Mayo Clinic in Florida), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Stephen D. Smith(Seattle Cancer Care Alliance), Corentin Orvain(Centre Hospitalier Universitaire d'Angers), Kamal Bouabdallah(Université de Bordeaux), Uttam K. Rao(Sarah Cannon), Marie‐Pierre Moles(Université d'Angers), Michael A. Spinner(Stanford Medicine), Maryam Rahimian(Beth Israel Deaconess Medical Center), Jakub Svoboda(UPMC Hillman Cancer Center)
Cited by 8
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k